Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EXAI

Exscientia (EXAI) Stock Price, News & Analysis

Exscientia logo

About Exscientia Stock (NASDAQ:EXAI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$4.49
$4.85
50-Day Range
$4.69
$5.96
52-Week Range
$3.80
$6.49
Volume
1.51 million shs
Average Volume
623,597 shs
Market Capitalization
$632.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Remove Ads
Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

EXAI Stock News Headlines

Exscientia and Recursion Merge to Revolutionize Drug Discovery
Recursion, Exscientia officially combine to advance drug discovery
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)
Recursion and Exscientia Merger Approved by Shareholders
Recursion, Exscientia shareholders approve proposed combination
See More Headlines

EXAI Stock Analysis - Frequently Asked Questions

Exscientia plc (NASDAQ:EXAI) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The business had revenue of $5.60 million for the quarter. Exscientia had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 882.09%.

Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share.

Exscientia's top institutional shareholders include Blue Trust Inc., Blue Trust Inc., Group One Trading LLC and Citadel Advisors LLC.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/15/2024
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EXAI
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$7.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+24.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-181,560,000.00
Net Margins
-882.09%
Pretax Margin
-904.93%

Debt

Sales & Book Value

Annual Sales
$25.60 million
Price / Cash Flow
N/A
Book Value
$2.54 per share
Price / Book
1.91

Miscellaneous

Free Float
109,324,000
Market Cap
$632.93 million
Optionable
Optionable
Beta
0.83
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:EXAI) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners